Last Updated: 11/27/2018
2018 News
- Posted: 11/27/2018
DCTD Releases A New Resource for Exploring Cell Line Transcriptional Responses to Anti-Cancer Agents: The NCI Transcriptional Pharmacodynamics Workbench - Posted: 11/27/2018
Olaparib after Initial Treatment Delays Ovarian Cancer Progression; Cancer Currents Blog Featuring Elise Kohn, MD - Posted: 11/19/2018
DCTD Staff Present at the 2018 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Posted: 11/09/2018
DCTD’s Cancer Therapy Evaluation Program Convenes 2018 Symposium on Mechanisms of Cancer Drug Resistance and Sensitivity - Posted: 10/25/2018
Study Improves the Quality of Biopsy Specimens for Cancer Research; Cancer Currents Blog Post Featuring Kate Ferry-Galow, PhD - Posted: 10/25/2018
Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer; Cancer Currents Blog Featuring Larissa Korde, MD - Posted: 10/25/2018
Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations; Cancer Currents Blog Featuring Paula Jacobs, PhD - Posted: 10/22/2018
DCTD’s Translational Research Program Announces Fiscal Year 2018 SPORE Grantees - Posted: 10/22/2018
DCTD’s Cancer Therapy Evaluation Program Convenes 2018 Early Drug Development Meeting - Posted: 10/04/2018
Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the Brain; Cancer Currents Blog Post Featuring Elad Sharon, MD, MPH - Posted: 10/04/2018
Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows; Cancer Currents Blog Post Featuring Carmen Allegra, MD - Posted: 09/12/2018
NCI’s Patient-Derived Models Repository Announces Its First Patient-Derived Cell Cultures and Cancer-Associated Fibroblasts Available to the Scientific Community - Posted: 09/12/2018
DCTD Convenes 2018 SPORE Workshop on Translational Research in Head & Neck/Thyroid Cancer; August 16-17, 2018 - Posted: 08/17/2018
Liquid Biopsy Test May Help Predict Risk of Late Breast Cancer Relapse; Cancer Currents Blog Post Featuring Lyndsay Harris, MD - Posted: 08/17/2018
Cetuximab with Radiation Found to Be Inferior to Standard Treatment in HPV-Positive Oropharyngeal Cancer (NCI Press Release) - Posted: 08/17/2018
Predictive Modeling for Pre-Clinical Drug Screening: Improving Models Derived from Observational Studies Using Machine Learning and Simulation; Center for Biomedical Informatics & Information Technology Blog Series Featuring James Doroshow, MD, and Yvonne Evrard, PhD - Posted: 08/17/2018
New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma; Cancer Currents Blog Post Featuring Elise Kohn, MD - Posted: 08/01/2018
DCTD Convenes Breast Cancer SPORE Workshop to Promote Translational Cancer Research; July 9, 2018 - Posted: 07/30/2018
Developing Biomarkers for Immunotherapy: A Conversation with Drs. Thurin and Chen; Cancer Currents Blog Post - Posted: 07/06/2018
NCI Convenes Workshop on Social Media and Clinical Trials; June 7-8, 2018 - Posted: 06/28/2018
Dr. Norman Coleman Receives the 2018 Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care
- Posted: 06/28/2018
Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia; Cancer Currents Blog Post Featuring Dr. Malcolm Smith - Posted: 06/12/2018
DCTD's Cancer Imaging Program Convenes 10th Annual Meeting of the Quantitative Imaging Network; May 17-18, 2018 - Posted: 06/05/2018
NCI-MATCH Precision Medicine Clinical Trial Releases New Findings, Strengthens Path Forward for Targeted Cancer Therapies (NCI Press Release) - Posted: 06/05/2018
TAILORx Trial Finds Most Women with Early Breast Cancer Do Not Benefit from Chemotherapy (NCI Press Release) - Posted: 05/30/2018
Dabrafenib-Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer; Cancer Currents Blog Post Featuring Dr. Larissa Korde - Posted: 05/30/2018
Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests; Cancer Currents Blog Post Featuring Dr. Nita Seibel - Posted: 05/21/2018
Schedule of DCTD Presentations at ASCO 2018 (June 1-5, 2018; Chicago, IL) - Posted: 05/17/2018
NIH Convenes Workshop on Cancer, Autoimmunity and Immunology; March 22-23, 2018 - Posted: 05/14/2018
Workshop on Dosimetry of Systemic Targeted Radiopharmaceutical Therapy (TRT); April 19-20, 2018 - Posted: 05/07/2018
Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers; Cancer Currents Blog Post Featuring Dr. Elise Kohn - Posted: 05/07/2018
Innovation and Biomarkers in Cancer Drug Development Meeting (November 29-30, 2018; Brussels, Belgium) - Posted: 04/24/2018
Workshop on Issues in Post-Treatment Surveillance; March 26-27 - Posted: 04/24/2018
NCI Expands Repository of Cancer Research Models: A Conversation with Drs. Doroshow and Evrard; Cancer Currents Blog Post - Posted: 04/03/2018
NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials; Cancer Currents Blog Post Featuring Dr. Jeff Abrams and Grace Mishkin - Posted: 03/29/2018
NIH-funded Study Shows Sorafenib Improves Progression-free Survival for Patients with Rare Sarcomas (NCI Press Release) - Posted: 03/20/2018
Schedule of DCTD Staff Presentations at AACR 2018 (April 14-18, 2018; Chicago, IL) - Posted: 03/05/2018
NCI’s Patient-Derived Models Repository Announces New Models Available to the Scientific Community - Posted: 03/05/2018
Can Oxygen “Microbubbles” Make Radiation Therapy More Effective?; Cancer Currents Blog Post Featuring Dr. Eric Bernhard - Posted: 03/05/2018
For Rare Melanoma, Checkpoint Inhibitors May Hold Substantial Promise; Cancer Currents Blog Post Featuring Dr. Elad Sharon - Posted: 02/13/2018
Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations; Cancer Currents Blog Post Featuring Dr. Elise Kohn - Posted: 02/13/2018
Study Identifies Potential Cause of Hearing Loss from Cisplatin; Cancer Currents Blog Post Featuring Dr. Percy Ivy - Posted: 01/24/2018
Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia; Cancer Currents Blog Post Featuring Dr. Rich Little - Posted: 01/16/2018
New Funding Opportunity Announcement: PAR-18-560: National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required)